TY - JOUR
T1 - Role of postoperative radiotherapy after pelvic lymphadenectomy and radical retropubic prostatectomy
T2 - A single institute experience of 415 patients
AU - Cozzarini, Cesare
AU - Bolognesi, Angelo
AU - Ceresoli, Giovanni Luca
AU - Fiorino, Claudio
AU - Rossa, Alberto
AU - Bertini, Roberto
AU - Colombo, Renzo
AU - Da Pozzo, Luigi
AU - Montorsi, Francesco
AU - Roscigno, Marco
AU - Calandrino, Riccardo
AU - Rigatti, Patrizio
AU - Villa, Eugenio
PY - 2004/7/1
Y1 - 2004/7/1
N2 - Purpose To evaluate the clinical benefit deriving from early (within 6 months) radiotherapy (ERT) after pelvic lymphadenectomy and radical retropubic prostatectomy for localized/locally advanced adenocarcinoma of the prostate in a single-institution series. Methods and materials We retrospectively analyzed 415 patients who underwent pelvic lymphadenectomy and radical retropubic prostatectomy between 1986 and 1998 for pT2b-pT4, pN0-pN1 prostate carcinoma. Of the 415 patients, 237 underwent ERT for adverse pathologic findings and 178 patients did not receive RT or underwent salvage RT ≤6 months (salvage or no RT [SNRT]). Results After a median follow-up of 62 months, the 8-year actuarial freedom from biochemical, local and systemic failure, and cause-specific survival rate was 69% vs. 31% (p
AB - Purpose To evaluate the clinical benefit deriving from early (within 6 months) radiotherapy (ERT) after pelvic lymphadenectomy and radical retropubic prostatectomy for localized/locally advanced adenocarcinoma of the prostate in a single-institution series. Methods and materials We retrospectively analyzed 415 patients who underwent pelvic lymphadenectomy and radical retropubic prostatectomy between 1986 and 1998 for pT2b-pT4, pN0-pN1 prostate carcinoma. Of the 415 patients, 237 underwent ERT for adverse pathologic findings and 178 patients did not receive RT or underwent salvage RT ≤6 months (salvage or no RT [SNRT]). Results After a median follow-up of 62 months, the 8-year actuarial freedom from biochemical, local and systemic failure, and cause-specific survival rate was 69% vs. 31% (p
KW - Adjuvant radiotherapy
KW - Prostatectomy
KW - Prostatic neoplasms
UR - http://www.scopus.com/inward/record.url?scp=2942590376&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2942590376&partnerID=8YFLogxK
U2 - 10.1016/j.ijrobp.2003.12.001
DO - 10.1016/j.ijrobp.2003.12.001
M3 - Article
C2 - 15183470
AN - SCOPUS:2942590376
VL - 59
SP - 674
EP - 683
JO - International Journal of Radiation Oncology Biology Physics
JF - International Journal of Radiation Oncology Biology Physics
SN - 0360-3016
IS - 3
ER -